154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7
-
High Light
154229-18-2 Pharmaceutical Intermediates
,Abiraterone Acetate
,Anti Cancer Abiraterone Acetate
-
Product NameAbiraterone Acetate
-
Synonyms[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] Acetate;(3β)-17-(3-pyridinyl) Androsta-5,16-dien-3-yl Acetate;Abiraterone Acetate, >=99%;Abirteroneacetate;ZYTIGA
-
CAS154229-18-2
-
MFC26H33NO2
-
MW391.55
-
EINECS620-314-7
-
Melting Point127-130°C
-
Boiling Point506.7±50.0 °C(Predicted)
-
Density1.14±0.1 G/cm3(Predicted)
-
Storage Temp-20°C Freezer
-
Purity99%
-
Place of OriginChina
-
Brand NameRUN
-
CertificationIOS9001
-
Model NumberRUN-Z
-
Minimum Order Quantity10g
-
Priceinquiry
-
Packaging Details10g 50g 100g 500g 1kg
-
Delivery Time3-7 days
-
Payment TermsT/T, MoneyGram, BTCcoin
-
Supply Ability1kg --100kg
154229-18-2 Abiraterone Acetate Anti Cancer Immunity C26H33NO2 620-314-7
SECTION 1: Basic information
| Abiraterone acetate Basic information |
| Product Name: | Abiraterone acetate |
| Synonyms: | Abiraterone Acotate;Abiraterone Acetate impurity;(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate;[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;(3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate;Abiraterone acetate, >=99%;Abirteroneacetate;ZYTIGA |
| CAS: | 154229-18-2 |
| MF: | C26H33NO2 |
| MW: | 391.55 |
| EINECS: | 620-314-7 |
| Product Categories: | Inhibitors;Inhibitor;API;DQM;Final material;Anti-cancer & immunity;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids |
| Mol File: | 154229-18-2.mol |
 |
|
| Abiraterone acetate Chemical Properties |
| Melting point | 127-130°C |
| Boiling point | 506.7±50.0 °C(Predicted) |
| density | 1.14±0.1 g/cm3(Predicted) |
| storage temp. | -20°C Freezer |
| pka | 5.31±0.12(Predicted) |
| form | powder |
| color | white to beige |
| Safety Information |
| WGK Germany | 3 |
| RTECS | BV7992100 |
| Abiraterone acetate Usage And Synthesis |
| Description | In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%). |
| Chemical Properties | Off-White Solid |
| Originator | Institute of Cancer Research, London (United Kingdom) |
| Uses | Abiraterone acetate is a novel steroidal inhibitor of human Cytochrome P450 (17α-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer. |
| Uses | Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011 for the treatment of castrationresistant prostate cancer. The drug, marketed under the trade name Zytiga, was originally discovered by researchers at the Cancer Research UK Centre for Cancer Therapeutics in 1990, developed by Cougar Biotechnology, and ultimately commercialized by Johnson & Johnson after its acquisition of Cougar in 2009. Abiraterone acetate inhibits CYP17A1—an enzyme expressed in testicular, adrenal, and prostatic tumor tissues—which has been implied in the production of testosterone and the proliferation of such tumor cell lines. |
SECTION 2: Hazard identification
2.1 Classification of the substance or mixture
Acute toxicity - Category 4, Oral
Reproductive toxicity, Category 2
2.2 GHS label elements, including precautionary statements
| Pictogram(s) | |
|---|---|
| Signal word | Warning |
| Hazard statement(s) |
H302 Harmful if swallowed H361 Suspected of damaging fertility or the unborn child |
| Precautionary statement(s) | |
| Prevention |
P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P203 Obtain, read and follow all safety instructions before use. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/... |
| Response |
P301+P317 IF SWALLOWED: Get medical help. P330 Rinse mouth. P318 IF exposed or concerned, get medical advice. |
| Storage | P405 Store locked up. |
| Disposal | P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal. |
2.3 Other hazards which do not result in classification
no data available
SECTION 3: Composition/information on ingredients
3.1 Substances
| Chemical name | Common names and synonyms | CAS number | EC number | Concentration |
|---|---|---|---|---|
| (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate(3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate17-(3-pyridyl)-5,16-androstadien-3 beta acetateAbiraterone AcetateAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3b)-Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate | (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate(3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate17-(3-pyridyl)-5,16-androstadien-3 beta acetateAbiraterone AcetateAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3b)-Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate | 154229-18-2 | - | 100% |
SECTION 4: First-aid measures
4.1 Description of necessary first-aid measures
If inhaled
Move the victim into fresh air. If breathing is difficult, give oxygen. If not breathing, give artificial respiration and consult a doctor immediately. Do not use mouth to mouth resuscitation if the victim ingested or inhaled the chemical.
Following skin contact
Take off contaminated clothing immediately. Wash off with soap and plenty of water. Consult a doctor.
Following eye contact
Rinse with pure water for at least 15 minutes. Consult a doctor.
Following ingestion
Rinse mouth with water. Do not induce vomiting. Never give anything by mouth to an unconscious person. Call a doctor or Poison Control Center immediately.
4.2 Most important symptoms/effects, acute and delayed
no data available
4.3 Indication of immediate medical attention and special treatment needed, if necessary
no data available
SECTION 5: Fire-fighting measures
5.1 Suitable extinguishing media
Use dry chemical, carbon dioxide or alcohol-resistant foam.
5.2 Specific hazards arising from the chemical
no data available
5.3 Special protective actions for fire-fighters
Wear self-contained breathing apparatus for firefighting if necessary.
SECTION 6: Accidental release measures
6.1 Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing mist, gas or vapours.Avoid contacting with skin and eye. Use personal protective equipment.Wear chemical impermeable gloves. Ensure adequate ventilation.Remove all sources of ignition. Evacuate personnel to safe areas.Keep people away from and upwind of spill/leak.
6.2 Environmental precautions
Prevent further spillage or leakage if it is safe to do so. Do not let the chemical enter drains. Discharge into the environment must be avoided.
6.3 Methods and materials for containment and cleaning up
Collect and arrange disposal. Keep the chemical in suitable and closed containers for disposal. Remove all sources of ignition. Use spark-proof tools and explosion-proof equipment. Adhered or collected material should be promptly disposed of, in accordance with appropriate laws and regulations.
SECTION 7: Handling and storage
7.1 Precautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
7.2 Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
SECTION 8: Exposure controls/personal protection
8.1 Control parameters
Occupational Exposure limit values
no data available
Biological limit values
no data available
8.2 Appropriate engineering controls
Ensure adequate ventilation. Handle in accordance with good industrial hygiene and safety practice. Set up emergency exits and the risk-elimination area.
8.3 Individual protection measures, such as personal protective equipment (PPE)
Eye/face protection
Wear tightly fitting safety goggles with side-shields conforming to EN 166(EU) or NIOSH (US).
Skin protection
Wear fire/flame resistant and impervious clothing. Handle with gloves. Gloves must be inspected prior to use. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
Respiratory protection
If the exposure limits are exceeded, irritation or other symptoms are experienced, use a full-face respirator.
Thermal hazards
no data available
Our products are sold all over the world, you can rest assured.